Cutaneous manifestations of the malignant carcinoid syndrome

Bell, Hazel Κ.; Poston, Graeme J.; Vora, Jiten; Wilson, N. J. E.

doi:10.1111/j.1365-2133.2004.06273.x

Cited by 121 publications

(72 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The presentation will often include a beefy tongue and red skin lesions localized to the face and neck. 6 In addition to the physical symptoms caused by carcinoid tumors and carcinoid syndrome, patients may also suffer from psychiatric complications. Results from two previous studies demonstrated the presence of depressive symptoms in half of patients with carcinoid tumors who had elevated urinary 5-HIAA levels.…”

Section: Discussionmentioning

confidence: 99%

Mood Change in a Patient with a Carcinoid Tumor

Sierzchula¹,

MacGregor²,

Onuscheck³

et al. 2016

Psychiatric Annals

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Mood Change in a Patient with a Carcinoid Tumor

Sierzchula¹,

MacGregor²,

Onuscheck³

et al. 2016

Psychiatric Annals

View full text Add to dashboard Cite

“…The prevalence of pellagra in serotonin-producing NET patients is about 5% [12] and especially reveals during the advanced stage of the disease [10]. Niacin deficiency might be underestimated in patients with a serotonin-producing NET.…”

Section: Discussionmentioning

confidence: 99%

“…In patients with serotonin-producing NETs, pellagra and other symptoms suggestive of tryptophan and/or niacin deficiency are reported [3,4,10,11,12]. Niacin supplementation resulted in a quick and substantial improvement in the symptoms of these patients [4,11].…”

Section: Introductionmentioning

confidence: 99%

Niacin (Vitamin B<sub>3</sub>) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor

Bouma¹,

Faassen²,

Kats-Ugurlu³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Background/Aims: Tryptophan is the precursor of serotonin and niacin (vitamin B₃). The latter is critical for normal cellular metabolism. Tryptophan and niacin can be deficient in patients with serotonin-producing neuroendocrine tumors (NETs). Niacin deficiency may lead to severe symptoms including pellagra. In patients with serotonin-producing NET, data on niacin status are scarce and niacin supplementation hardly receives attention. We aimed to assess the niacin status before and after supplementation in these patients. Methods: We identified serotonin-producing NET patients who had received oral niacin supplementation (mean dose 144 mg daily) for tryptophan deficiency and/or pellagra-associated symptoms. Presupplementation plasma tryptophan levels and niacin status based on the urinary niacin metabolite N¹-methylnicotinamide (N¹-MN) before (n = 42) and after the start of the supplementation (in 34 paired samples) were assessed. Reference values for urinary N¹-MN levels were established in 133 healthy individuals. Results: The mean presupplementation plasma tryptophan level was 31.8 ± 9.7 µmol/l (reference value 40.0-70.0). Presupplementation urinary N¹-MN levels were lower in patients (median 17.9 µmol/24 h, range 2.6-70.3) compared to healthy controls (median 43.7 µmol/24 h, range 9.5-169.3, p < 0.0001) and below normal in 45% of the patients. Niacin supplementation increased urinary N¹-MN levels to high normal levels (median 55.5 µmol/24 h, range 7.4-489.0) in 86% of the niacin-deficient patients. Conclusion: In serotonin-producing NET patients, niacin deficiency is prevalent. Therefore, urinary N¹-MN deserves to be included in their standard biochemical evaluation. Niacin supplementation normalizes the niacin status in most niacin-deficient serotonin-producing NET patients. A prospective study is warranted.

show abstract

“…En effet, des cas de carcinome é pidermoïde ont é té dé crits chez des patients ayant une morphé e gé né ralisé e. Cette association ne semble pas ê tre fortuite é tant donné la rareté des morphé es gé né ralisé es et l'utilisation fré quente de la Puvathé rapie dans le traitement de ces sclé rodermies [14,16,17] ; -on peut observer une association entre morphé e et certains cancers, particuliè rement les cancers colorectaux [6,8], tel est le cas de notre observation, le cancer du sein [9] et les syndromes carcinoïdes [1] ; -la morphé e peut survenir dans des zones qui sont irradié es chez des patients ayant dé jà un cancer, notamment du sein [2] ; -quelques cas de morphé e induite par des traitements chimiothé rapiques pour un cancer ont é té dé crits [7] ; -enfin, aspect sclé rodermiforme que peuvent prendre des mé tastases cutané es de certains cancers, notamment le cancer de la prostate [13].…”

Section: Commentairesunclassified

Morphée généralisée révélatrice d’un adénocarcinome rectal

et al. 2008

View full text Add to dashboard Cite

The term Scleroderma unites a heterogeneous group of disease of conjunctive tissue with, unknown in etiology and wich have together an induration of the skin. The association of the scleroderma and neoplasy were not clearly reported. We report an observation of association between a generalised morphea and a rectal cancer. Ms D.B., aged of 62 years old, with no pathologic antecedents, was hospitalised in 2005 for multiple plaques, white, indurated, and localised in the trunk and the lower extremities. The lesions have evolved for one month and a half. The diagnosis of generalised morphea was suspected. The cutaneous biopsy concluded a scleroderma. The antinuclear antibody (anti-Scl 70) was negative. The patient was treated by prednisone (0,75 mg/kg/day) with a slight amelioration. During his hospitalisation, the patient suffered from constipation and the questionnaire showed a sensation of intrarectal body since 3 months. The rectoscopy revealed a big rectal tumor. The rectal biopsy concluded to differentiated luberkinien adenocarcinoma. This rectal tumor was treated by a radiotherapy associated with chemotherapy then followed by surgery. The morphea worsened 2 months later. The association between the generalised morphea and the cancer is rare. There is many arguments to paraneoplasic character of generalised morphea.

show abstract

Cutaneous manifestations of the malignant carcinoid syndrome

Abstract: This descriptive case series indicates that cutaneous features are not uncommon in the syndrome. They are readily diagnosed on clinical examination, and may be useful indicators of disease activity and prognosis.

Cited by 121 publications

References 14 publications

Mood Change in a Patient with a Carcinoid Tumor

Mood Change in a Patient with a Carcinoid Tumor

Niacin (Vitamin B<sub>3</sub>) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor

Morphée généralisée révélatrice d’un adénocarcinome rectal

Contact Info

Product

Resources

About